ASCO 2021: Updates in CRC

ASCO 2021: Updates in CRC

Final Results Support Pembrolizumab as Standard of Care in MSI-H/dMMR Metastatic Colorectal Cancer

Pembrolizumab significantly improved PFS, but not OS, when compared with chemotherapy in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer...

Cancer Therapy Advisor
Capecitabine Maintenance Improves Progression-Free Survival in Metastatic Colorectal Cancer

Capecitabine maintenance improved PFS, but not OS, when compared with active monitoring in patients with metastatic colorectal cancer, according to data from the FOCUS4-N trial.

Cancer Therapy Advisor
Pembrolizumab Shows Continued PFS Benefit in MSI-H/dMMR Metastatic Colorectal Cancer

Pembrolizumab demonstrates continued PFS benefit, with a trend for OS benefit, as first-line therapy for patients with MSI-H mCRC, compared with chemotherapy, in the final analysis of KEYNOTE-177.<

ASCO Daily News

Chemotherapy/Local Excision Avoids Proctectomy in Rectal Cancer

Chemotherapy and local excision led to organ preservation in over half of early-stage rectal cancer patients in a small study, but follow-up was only a median of 15.4 months. Even so...

'Smart Bomb' Salvage in HER+ Metastatic CRC

The higher the HER2 expression, the more benefit patients get from the antibody-drug conjugate trastuzumab deruxtecan for HER2-positive metastatic colorectal cancer in the salvage setting...

Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer

Guardant Health presents new data at the 2021 ASCO Annual Meeting showing that its LUNAR-2 blood test is a highly sensitive test that can detect CRC in early-stage cancer patients.

ASCO: Merck's LAG-3 antibody boosts Keytruda in hard-to-treat colon cancer

Favezelimab helped pembrolizumab make a dent in metastatic CRC in very sick patients with microsatellite stable tumors, according to phase 1 data being presented at the 2021 ASCO Annual Meeting.

ASCO 2021 Showcases the Impact of Caris' Molecular Science Data in Advancing Cancer Care

Over 20 studies to be presented at ASCO, including data on the comprehensive characterization of NT pathway alterations in CRC and Globo H expression in metastatic CRC.

Servier Highlights Novel Approaches to Treating Cancer at the ASCO and EHA 2021 Annual Meetings

Servier today announced that data will be presented from multiple studies spanning an array of hard-to-treat solid tumor types, including CRC, at the 2021 ASCO Annual Meeting.

CRC Cancer Care and Research: What to Expect at ASCO 2021

Sessions will be available on demand beginning Friday, June 4 at 9 AM (ET), with the exception of the Highlights of the Day and broadcast sessions. Broadcast sessions will feature live Q&A with speakers.

Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021

Antengene announced that 15 studies and results of selinexor will be presented at the 2021 ASCO Annual Meeting, including data on the tolerability and activity of selinexor plus pembrolizumab for C


source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)